I'd recommend sending an email to Mr. Lisenby rather than emailing prospective clients as a shareholder. Mr. Lisenby has shown himself to be very receptive to similar recommendations for prospects and I think it would add more weight if the company made initial contact. Shareholders of a penny stock with only limited information on the BioHarp might not be taken seriously, especially if they have specific technical questions that we cannot answer.